In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing Size, Share & Trends Analysis Report By Test Type, By Technology, By Application (Cytotoxicity Testing, Genetic Toxicity Testing), By Method, By Region, And Segment Forecasts, 2021 – 2028
New York, Oct. 19, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report "In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing Size, Share & Trends Analysis Report By Test Type, By Technology, By Application, By Method, By Region And Segment Forecasts, 2021 – 2028" – https://www.reportlinker.com/p06176718/?utm_source=GNW
In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing Growth & Trends
The global in-vitro toxicology assays market size for cannabis and nicotine testing is expected to reach USD 2.9 billion by 2028. The market is expected to expand at a CAGR of 11.2% from 2021 to 2028. Growing adoption of high throughput techniques in cannabis testing, legalization of medical cannabis, and growing awareness regarding the potential hazards of nicotine consumption have majorly driven the market throughout the forecast period.
The legalization of medical cannabis is underway globally, including in countries such as Germany, Australia, and Israel.The market is gaining momentum in the Asia Pacific region, with Thailand having fully legalized medicinal cannabis.
Thus, increasing legalization of medical cannabis is expected to drive the market growth to a major extend. In addition, technological advancements in cellular assays have boosted the market growth.
COVID-19 has become a catalyst for changing the traditional use of cannabis.Owing to the pandemic, the leading scientific community and market competitors are now focusing on deciphering the potential of cannabis to prevent SARS-CoV-2 infection.
Companies have reported the increase in the sale of cannabis as some states/countries have declared cannabis as an essential medicine during the pandemic.
In-vitro Toxicology Assays Market For Cannabis And Nicotine Testing Report Highlights
• Nicotine testing accounted for the largest revenue in 2020 and is expected to continue the trend in the forecast period owing to increasing safety concerns associated with nicotine products
• Cannabis testing is expected to witness gradual growth through 2021-2028 owing to the rising acceptance of cannabis for medical use
• 3D cell culture technology is expected to grow at substantial CAGR owing to the increasing popularity of drug development and toxicity testing
• Cytotoxicity testing designing accounted for the highest market revenue in 2020 owing to advancements in different tools for evaluating the cytotoxic effects of nicotine-containing products
• North America has emerged as the highest revenue-generating region in 2020, owing to the prevalence of cancer, presence of key players, and developed healthcare infrastructure
• Asia Pacific is anticipated to witness the fastest CAGR throughout the forecast period. It is anticipated that China and India are contributing majorly to the regional market’s growth
• Key players are undertaking various strategic initiatives such as mergers and acquisitions to maintain their presence in the market
• In August 2020, Eurofins Scientific purchased approximately 136 smaller labs within 3 years from 2014 to 2019, accounting for a total expenditure of USD 3.4 billion in these acquisitions
Read the full report: https://www.reportlinker.com/p06176718/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
Atea Pharmaceuticals said Tuesday its Merck-rivaling antiviral Covid pill failed in a midstage test, leading AVIR stock to crash.
Photo by Towfiqu barbhuiya on Unsplash Broad agreement in the world of science can be a rarity. However, one thing that public health leaders active in the fight against COVID-19 can agree on, is the urgent need for oral, pill-based treatments that are effective at halting disease progression, can get — and keep — people out of the hospital and can reduce mortality. One key group of COVID-19 patients who are in desperate need of treatment options are those moderately severe patients in hospital
Anavex Life Sciences and Affimed both sport unique drug development platforms that could be worth billions.
The company applied in April for Food and Drug Administration approval to sell the new product. Now that process could take a bit more time.
Biogen and Ionis' approach to Lou Gehrig's disease flopped over the weekend, leading IONS stock to collapse to a five-year low Monday.
Edesa Biotech Inc (NASDAQ: EDSA) is trading higher Tuesday after the company announced additional results from the Phase 2 part of the ongoing Phase 2/3 study of EB05 in COVID-19. Edesa reported that EB05 demonstrated mortality reductions in multiple patient groups beyond the initial findings. The company said it believes EB05 regulates the overactive and dysfunctional immune response associated with Acute Respiratory Distress Syndrome, which is the leading cause of death in COVID-19 patients. "
Failing to enroll in Medicare can lead to some steep penalties, and that’s just as true for Medicare Part D, which covers prescription drugs. Eight in 10 Medicare beneficiaries were not aware of the late enrollment penalty for Part D, according to a survey of more than 1,000 people from MedicareAdvantage.com. The penalty applies to people who do not have “creditable drug coverage” for 63 days.
Public-health experts hope that a Covid-19 pill could be an affordable, convenient tool to reduce the human cost of the virus.
A recent survey found that most business executives support the vaccine and testing mandates, but have concerns over their implementation.
U.S. regulators 'will start moving [booster] recommendations to earlier ages,' predicts Albert Bourla.
Shares of MannKind (NASDAQ: MNKD), a company working to develop inhaled therapeutics, were down 18% as of 11:59 a.m. EDT on Monday after an inspection issue derailed its hopes of approval for Tyvaso DPI, a lung disease therapy it developed with United Therapeutics (NASDAQ: UTHR). According to United Therapeutics' Securities and Exchange Commission filings, it owns two patents for treating PAH through inhalation that expire in 2024. The Food and Drug Administration's complete response letter didn't cite issues with MannKind's operations or even the clinical data submitted by the two companies.
Artificial intelligence is coming for the $11 trillion doctor industry, and it could change how you and your doctor interact for decades to come
These dividend stocks provide sustainable and growing dividends, which are nearly triple the S&P 500's yield.
The FDA rejected Revance Therapeutics' frown lines treatment, depressing RVNC stock which fell to an 18-month low on Monday.
Is Pfizer stock a buy after the CDC recommended Covid booster shots for people age 65 and older, and otherwise vulnerable Americans?
It looks like the gene therapy market is a haunted house, but growing biotech Repligen might be the treat investors need this Halloween.
Even though COVID cases and hospitalizations have been decreasing over the past month, one doctor doesn’t think the pandemic is ending any time soon.
Lemon showed multiple examples of Fox News anchors quickly turning the news of Powell’s passing into a discussion about vaccines. "Shame on them."
The Week In Psychedelics Atai Launches ‘Precision Psychiatry’ Subsidiary The Psychedelics Sector Reaches 50 Public Companies Listed In The U.S. Pasithea Therapeutics To Launch Its First Ketamine Clinic In The UK PharmaTher Receives FDA Orphan Drug Designation For Ketamine Use In Complex Regional Pain Syndrome Pennsylvania Gets A Psilocybin Bill The Milestone Round Atai Launches ‘Precision Psychiatry Subsidiary Atai Life Sciences (NASDAQ: ATAI) announced the formation of a new subsidiary, called
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Neovasc Inc. (NASDAQ: NVCN) is a medical device company focused on developing, manufacturing, and marketing products for the cardiovascular market. Neovasc is a leading developer of minimally invasive transcatheter mitral valve replacement technologies as well as minimally invasive devices for the treatment of refractory angina. Refractory ang